New York, NY (PRWEB) May 14, 2013
Kantar Health, a leading global healthcare consulting firm, today announced that three of its thought leaders will present at the 2013 PBIRG Annual General Meeting in Naples, Fla., May 19-22.
Gordon Gochenauer, director, will present “Market Dynamics – Interactions and the Changing Landscape” at 2:00pm on Sunday, May 19. This session will explore the evolving dynamics of the oncology market and provide a high-level view of the key players involved in delivering healthcare to patients with cancer.
Gochenauer and Stephanie Hawthorne, Ph.D., director, will present “Biomarkers in Oncology: Do They Help or Hurt?” at 3:00pm on Monday, May 20. This presentation will review the evolving oncology landscape with regard to biomarker segmentation; discuss key factors to consider when developing a drug in a biomarker-defined population; and highlight the impact on drug delivery, payer perception, affordability and access.
Bob Ramsey, Ph.D., senior vice president, will participate in the Q&A session “What did they do to my forecast!?” at 9:30am on Wednesday, May 22. This discussion will shed light on how panelists cope with risk and uncertainty in forecasts that they receive or prepare.
More information on the conference can be found at: http://www.pbirg.com/NetworkingEvents/View.aspx?id=82
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to the world’s leading pharmaceutical, biotech, and medical device and diagnostic companies. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and marketing expertise to help clients launch products and differentiate their brands in the marketplace.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from pre-clinical development to launch, acting as catalysts to successful decision making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit http://www.kantarhealth.com.